Biogen Inc. (BIIB) Earnings Call Transcript & Summary
October 21, 2020
Earnings Call Speaker Segments
Joe Mara
executiveGood morning, and thanks for joining us for Biogen's third quarter 2020 earnings call. To get started, I'd ask that you visit the Investors section of biogen.com, where you'll find our earnings release along with the related financial tables — among them a reconciliation of the GAAP to non-GAAP financial measures we'll be covering today. Tables 1 and 2 contain our GAAP financials, while Table 3 offers a reconciliation of our GAAP to non-GAAP financial results as well as our GAAP to non-GAAP financial guidance. In our view, non-GAAP financial results give a better picture of the ongoing economics of our business and show how we manage it internally. Slides are also up on our website, and they track the discussions tied to this call. I want to note that we'll be making forward-looking statements, which rest on our current expectations and beliefs. Such statements carry certain risks and uncertainties, and our actual results may differ materially. For more detail, I'd suggest reviewing the risk factors covered in our SEC filings. Joining me today are our Chief Executive Officer, Michel Vounatsos; Dr. Al Sandrock, EVP, Research and Development; and our CFO, Mike McDonnell. With that, I'll hand the call over to Michel.
Michel Vounatsos
executiveHi, everyone, and thank you for joining us today. You're all aware that the Advisory Committee meeting regarding aducanumab will be held on November 6th. That is our number one priority, and we're working hard to be ready for it. Meanwhile, the TECFIDERA situation in the U.S. is clearly a challenge in the near term, and we'll address that. Before I continue, I'd like to welcome Mike McDonnell, our new CFO. With his experience and track record, he's well positioned to make a significant contribution to Biogen, and I know he's looking forward to meeting many of you. Now, let me review some important recent developments. To start, we're very pleased the FDA has agreed to review our BLA for aducanumab under Priority Review, and they've indicated they hope to take action sooner if they can. As I mentioned, the Advisory Committee meeting is obviously a key milestone on the road to a possible approval, and we're hard at work getting ready to participate and present our thinking on the clinical data we've gathered. Turning to markets outside the U.S., we submitted a marketing authorization application in Europe earlier this month, and we're preparing a regulatory filing in Japan after our recent former meeting with the PMDA. Here in the U.S., we've continued to make progress. We kept our attention on the right kind of interaction with scientific experts and treatment centers, on articulating what aducanumab offers, and on building partnerships among a range of stakeholders, all to get ready for a possible launch of the first drug able to alter the trajectory of Alzheimer's disease in a meaningful way. In markets beyond America, our preparations for launch keep accelerating, especially across Europe and Japan. In addition to aducanumab, we keep moving forward the rest of our Alzheimer's pipeline, which includes BAN2401 in Phase 3 as well as several tau-directed initiatives. Turning to neurodegeneration, we're excited to partner with Denali, an innovative leader in neuroscience that's breaking new ground on treatments for brain disorders. Through this alliance, we gain a mid-stage small molecule LRRK2 inhibitor program, broadening our portfolio of possible Parkinson's disease therapies spanning several modalities. In addition, we secured exclusive option rights to two neurodegenerative disease programs that leverage Denali's novel Transport Vehicle platform, one of which involves amyloid beta antibodies. Given this extensive pipeline, aducanumab's ongoing regulatory review, and our new partnership with Denali, we feel strongly positioned to spearhead efforts against Alzheimer's and Parkinson's alike — the two most prevalent neurodegenerative conditions, ranking first and second, where innovative treatment options are desperately needed. On a wider level, our extensive pipeline keeps growing and being advanced, and at present it comprises 30 clinical assets, 8 of which are either in Phase 3 or field, among them the newly launched Phase 3 program for dapirolizumab pegol in lupus alongside UCB. Just as we've shown before, our dedication is to getting the greatest possible returns for shareholders while pursuing the goal of delivering novel treatments to patients—an effort requiring careful consideration of every investment we make, near-term and far-term alike. Let me explain how we see Biogen strategically, because we hold the view that at this moment we're in a transitional period defined by several inflection points coming into view. While we navigate the decline of TECFIDERA within the United States, our company stays committed to executing our strategy effectively. Neuroscience is where we hold the leading position. Our core capabilities set us apart, and our goal is to harness breakthrough science to tackle the enormous unmet medical need that exists in this area. What we're doing is applying a deeper comprehension of disease biology—genetics included—along with progress in biomarkers, for instance innovative brain imaging, to lower the risk involved in creating treatments for numerous conditions that were previously intractable. We're building on a strong track record from our work in MS, SMA and biosimilars, and we see ourselves entering a new phase that brings major clinical data releases and opportunities to generate value. We'll continue working to unlock the full promise of our broad MS lineup, including the launch of VUMERITY as well as life cycle management efforts for TYSABRI and the Interferon. Despite intensifying competition, we stay confident that SPINRAZA will continue to expand and serve as a foundation of care, thanks to the efficacy and safety profile in SMA that is the most well-established. From pre-symptomatic infants through to adults, SPINRAZA has shown sustained benefits that are clinically meaningful, and because of its safety profile, we've been able to start evaluating a higher dose that might deliver even greater efficacy. Biosimilars represent yet another possible growth engine for us, while also creating headroom for innovation; our work aims at expanding into the U.S and China, with the possibility of commercializing two fresh ophthalmology biosimilars that carry a worldwide market opportunity of roughly $11 billion. On an important note, Samsung Bioepis announced recently that the EMA accepted the Marketing Authorization Application for SB11, a potential biosimilar that references Lucentis; our optimism persists regarding the chance to launch aducanumab as the first therapy capable of meaningfully altering the course of Alzheimer's disease, and for the company this will serve as a significant growth driver both near term and long term; beyond aducanumab, we believe our pipeline might unlock a second wave of growth during the mid 2020s, powered by fields like ophthalmology, stroke, lupus and ALS. Importantly, by the close of 2021, we anticipate 6 data readouts at the mid to late stage. Our plan is to keep chasing external business development possibilities so our pipeline expands further; across a span of just under 4 years, we have committed close to $5 billion toward business development and completed 20 transactions. Looking ahead, we'll keep giving priority to keeping our organization stable in support of the current portfolio, all while getting ready for the possible introduction of a number of new products, beginning with aducanumab; our focus will land on diligent execution, seizing every chance for efficiency and cost savings. To sum up, we have kept executing our strategy well. We think we're set up well to help patients today and down the road, since we've assembled a collection of franchises by drawing on how closely linked our extensive neuroscience pipeline is. Our financial footing is quite strong, and our focus will remain firmly on generating the greatest possible long-term worth for shareholders. At this point I'll pass it to Al, who'll provide a more complete report on our recent R&D achievements.
Alfred Sandrock
executiveThank you, Michel, and good morning to all of you. To start, I want to express appreciation to the Biogen team for the effort they've put in, which has driven meaningful headway in moving our R&D programs forward. That covers achievements in several important areas, including the regulatory submissions for aducanumab, advances in the pipeline, and business development efforts. Beginning with Alzheimer's disease, and as Michel noted, we are navigating the regulatory processes for aducanumab across the globe. In addition, we are actively getting ready for the FDA advisory committee meeting scheduled for November 6. Still on Alzheimer's disease, Eisai, our collaboration partner, has dosed its first patient in the AHEAD 3 to 45 clinical program, which has been set up to assess BAN2401 in people who have preclinical Alzheimer's disease. From what this trial yields, we are hoping to find out if BAN2401 is able to hold back the advancement of amyloid and tau pathology and lessen cognitive decline during the earliest phases of Alzheimer's disease. During this quarter, we also shared news of an exciting partnership with Denali Therapeutics aimed at jointly developing and jointly commercializing Denali's small molecule LRRK2 inhibitor DNL151 for Parkinson's disease, which ranks as the second most common neurodegenerative disease. LRRK2 acts as a negative regulator of lysosomal function, and specific mutations within the LRRK2 gene raise the likelihood of Parkinson's disease; we intend to study the therapeutic potential of LRRK2 kinase inhibition in patients both with and without known genetic risks for Parkinson's disease. It is our hope that 151 might become a first-in-class oral therapy capable of slowing the disease's progression. This partnership additionally grants us an exclusive option to license two preclinical programs that draw on Denali's Transport Vehicle platform. That platform has been engineered to boost the brain uptake of large therapeutic molecules by making use of the transferrin receptor, which is heavily expressed at the blood-brain barrier. One of those two programs is aimed at improving delivery of an anti-beta amyloid antibody across the blood-brain barrier. We are delighted to be working together on this platform with Denali, which is a pioneer in improving how large molecules are delivered into the central nervous system. Turning now to our MS portfolio, at last month's AdComs meeting, we shared new data from the EVOLVE MS-2 trial that further strengthened the clinically meaningful improvement in gastrointestinal tolerability tied to VUMERITY when compared with TECFIDERA. More specifically, patients on VUMERITY showed a reduced likelihood of having GI symptoms that got in the way of daily activities or were linked to missed work, and they used less concomitant medication for treating GI symptoms. Additionally, at ECTRIMS, an analysis of real-world data among patients receiving TYSABRI extended interval dosing revealed no significant differences in the rates of new T2 lesions, T2 lesion volumes, or brain atrophy on brain MRI scans relative to patients on the currently approved every 4-week dosing regimen. These findings add to a growing body of evidence suggesting that TYSABRI extended interval dosing delivers efficacy similar to standard dosing, while lowering the risk of PML. Whether extended interval dosing matches the standard dosing regimen in efficacy is currently being evaluated prospectively in the ongoing NOVA study, with results anticipated next year. Also, we shared data from the real world demonstrating that treatment with TYSABRI was linked to meaningful gains in 9 of 12 domains of neuro quality of life reported by patients. In contrast, those who received OCREVUS showed gains in 4 of 12 domains. Now, regarding our MS pipeline, we were sorry to find that AFFINITY, the Phase 2b trial of opicinumab, failed to hit either its primary endpoint or its secondary endpoints. Because of that, we've chosen to halt further development of opicinumab. Even so, our dedication to the therapeutic strategy of repairing the central nervous system remains, and we continue to believe remyelination could deliver therapeutic value for people with MS. We're still examining the substantial data set from this trial to better guide our MS research in this space, including work on BIIB061. Shifting to neuromuscular disorders, after productive talks with the FDA, we're moving forward with plans for a trial to assess the benefit of tofersen when started in presymptomatic carriers of SOD1 mutations tied to ALS. Much like the NURTURE trial of SPINRAZA in SMA, this trial is built to assess whether tofersen can delay clinical onset or slow ALS disease progression when begun before clinical symptoms appear. We intend to launch this trial next year. Also in ALS, I'm pleased to share that we've dosed the first patient in our Phase 1 trial of BIIB105, an antisense oligonucleotide aimed at ataxin-2. Ataxin-2 was first identified as a modifier of TDP-43 toxicity, a pathology found in more than 90% of the ALS population, which suggests that lowering ataxin-2 might be therapeutic across most ALS populations, apart from those whose disease is due to SOD1. In addition, I'd like to give an update on our SMA gene therapy asset BIIB089. The FDA had earlier put a clinical hold on BIIB089 because of dorsal root ganglion toxicity, a pathology often seen in preclinical studies and one that may also arise after use of the currently available AAV mediated SMA gene therapy. So we've decided to stop BIIB089 and will instead concentrate on pursuing next generation SMA gene therapy technology that we think will tackle the DRG toxicity. Finally, we're pleased to announce that, working with UCB, we've dosed the first patient in our Phase 3 program for dapirolizumab pegol in patients with systemic lupus erythematosus with active disease, even though they're on standard of care therapies. To sum up, we keep building and advancing a deep neuroscience pipeline that aims to enhance — to address patients' needs by drawing on both organic growth and external collaboration. This approach is shown by our recent agreement with Denali and also Scribe Therapeutics, where we're pursuing cutting edge CRISPR technology to potentially develop gene therapies for ALS. We believe this combination of internal development and external collaboration lets us maximize the value of our R&D programs and offers a source of sustained innovation to help drive the company's long-term growth. At this point, I'll hand things over to Mike.
Michael McDonnell
executiveThanks, Al. Morning, everybody. It's great to be part of Biogen now, and I can't wait to meet lots of you. In spite of generic TECFIDERA recently coming onto the scene and COVID-19's ongoing effects, Biogen delivered yet another solid quarter, since we keep executing well; our financial footing stays very strong, with substantial cash and financial capacity allowing us to keep growing the business over the long term. Next, I'll walk you through how we did financially this quarter and give you an update on our guidance for the full year. Q3 total revenue came to $3.4 billion, which is 6% lower than the same period a year ago. Generic TECFIDERA entry largely drove that decrease, and it includes a currency headwind of 1%. Total MS revenue, with OCREVUS royalties included, reached $2.3 billion, down 4% from the prior year. During the third quarter, MS revenue started feeling the effect of multiple TECFIDERA generics entering the U.S., while TECFIDERA revenue outside the U.S. for Q3 totaled $283 million, up 1% year over year, with patients continuing to grow. In the quarter, VUMERITY trends improved, among them a rising count of new starts. Given its differentiated GI tolerability profile, as Al noted, we think VUMERITY can be a significant product. TYSABRI posted a strong quarter, with Q3 global revenue of $516 million, up 7% from the prior year; we were happy to see TYSABRI's global patient growth continue at 4% versus the prior year. In our view, TYSABRI is well-positioned to take on a growing role in treating MS. Also, we're pursuing several key initiatives, among them subcutaneous administration, a home infusion option, and an extended interval dosing option. Now on to SMA. Third quarter SPINRAZA revenue globally was $495 million, a 10% decrease from the prior year and flat compared with the prior quarter. Within the U.S., SPINRAZA revenue fell 23% year over year, as COVID-19 keeps affecting both new starts and maintenance doses, along with added competition. Beyond the U.S., SPINRAZA revenue held steady versus the prior year and rose 10% from the prior quarter. Even though COVID-19 and new competition have weighed on SPINRAZA, we see room for global growth, thanks to a very strong efficacy and safety profile and a substantial number of untreated patients throughout many established and emerging markets. Turning to our biosimilars business. This quarter's revenue was $208 million, up 13% compared with Q3 2019. Although Q3 biosimilars revenue returned to growth, it kept taking a hit from fewer new treatments and reduced clinic capacity for immunology patients because of COVID-19. Our first and biggest biosimilar, BENEPALI, has turned into the most prescribed etanercept product throughout Europe. We figure roughly 220,000 patients are now on our biosimilars across Europe, and we see room to keep expanding there, plus potentially in the U.S. and other regions. Anti-CD20 revenue overall in Q3 came to $560 million, which is down 6% compared with the same period last year. Higher OCREVUS royalties were offset by lower RITUXAN revenue stemming from COVID 19, along with ongoing biosimilar erosion — something we anticipate will keep weighing on RITUXAN. Other revenue altogether rose 15% in the third quarter compared with Q3 2019, reaching roughly $126 million. Now let's move to expenses. GAAP R&D expense for Q3 was $1.1 billion, equal to 34% of revenue. Non-GAAP R&D expense, after excluding $601 million tied to our Denali collaboration, came to $540 million, or 16% of revenue. Starting in Q3, significant upfront payments for major collaboration and licensing deals are now left out of non-GAAP R&D expense, so that our core operating performance is better reflected. On a year-to-date basis, non-GAAP results reflect this shift too, since the $125 million upfront payment for the Sangamo collaboration in the second quarter of 2020 is likewise now excluded from non-GAAP R&D expense. GAAP SG&A expense for Q3 was $573 million, while non-GAAP SG&A was $569 million, with both amounting to 17% of revenue. Inside the U.S., we are shifting some TECFIDERA resources over to back the launch of VUMERITY and aducanumab, though we'll keep fully supporting our wider MS portfolio. Beyond that, we're stepping up commercial readiness for aducanumab, which will put some upward pressure on SG&A. Even so, we'll keep managing operating expenses carefully, as we always do, to stay efficient throughout the organization. Our effective GAAP tax rate for Q3 of this year was about 25%, up from roughly 12% in the third quarter of 2019. That rise mainly reflects prior year favorability from Swiss tax reform, together with current year unfavorability driven largely by non-cash deferred tax adjustments tied to TECFIDERA. For the third quarter of 2020, our effective non-GAAP tax rate was about 18%, up from roughly 16% in the third quarter of 2019. GAAP net income for the third quarter was $702 million, and non-GAAP net income was $1.4 billion. GAAP diluted earnings per share for the third quarter came to $4.46, down 47% from the prior year, while non-GAAP diluted EPS was $8.84, down 4% from the prior year. We bought back roughly 4.5 million shares during Q3, for a total value of about $1.3 billion. The share repurchase program authorized in December of 2019 was finished as of September 30, 2020, and our Board of Directors has approved a new $5 billion share repurchase program. During Q3, we brought in about $1.2 billion in net cash flows from operations. Capital expenditures for Q3 were $84 million, and free cash flow was approximately $1.1 billion. At the close of the quarter, we held $4.6 billion in cash along with marketable securities, plus $7.4 billion of debt. On top of that, as of the quarter's end, our $1 billion revolving credit facility had not been drawn upon. Now let me give you an update on the full year guidance for 2020. The last time we updated that guidance was in July, and at that point it assumed there would be no generic entry for TECFIDERA. In the third quarter, we started feeling the effects of generic competitors, with more than 10 TECFIDERA generics approved and at least 6 currently on the market, at discounted prices of roughly 90%. Our guidance bakes in substantial erosion for TECFIDERA during the fourth quarter of 2020, and how fast that happens is hard to forecast. Consequently, we now anticipate full year revenue in the range of approximately $13.2 billion to $13.4 billion. For full year 2020, we expect GAAP diluted EPS of between $25.50 and $26.50, while non-GAAP diluted EPS should land between $32.50 and $33.50. One thing to note: this range leaves out the upfront payments tied to the Sangamo and Denali collaborations in the second and third quarters of 2020, respectively. The upfront payment for the Q2 Sangamo transaction works out to about $0.65 per share. It's worth pointing out that this guidance doesn't factor in possible effects from new acquisitions or large business development transactions, since both involve elements that are difficult to predict. This financial guidance also presumes that foreign exchange rates as of September 30, 2020 stay in place through the rest of the year. At this point I'll hand the call back to Michel for his closing remarks.
Michel Vounatsos
executiveThanks, Mike. At Biogen, we've stayed committed to executing well throughout our main operations in MS, SMA, and biosimilars, and we're still pushing forward with our plan to develop a portfolio spanning multiple franchises. I'd like to restate our dedication to boosting shareholder returns and incorporating innovative involvement both right now and in the future; achieving this means we must keep distributing capital in ways that are efficient, effective, and suitable. As shown previously, we'll consistently work toward an ideal capital structure and pursue outstanding gains from the investments we undertake. Once more, we're getting ready in earnest for the aducanumab Advisory Committee and a possible rollout. The unmet medical need and societal expense related to Alzheimer's are enormous and growing. In the U.S., Alzheimer's imposes an annual cost burden of roughly $550 billion, and caring for someone with the disease may exceed $0.5 million. Alzheimer's robs numerous patients of their independence. Roughly 75% of individuals with Alzheimer's disease reside in a nursing home by age 80, at an approximate yearly cost of $100,000 per patient. Should aducanumab gain approval, it would mark an extraordinary breakthrough for patients, their loved ones, and society overall, and it will serve as a key growth catalyst for the company in both the near and longer term. Lastly, we're concentrating on furthering our wider mission as an entity, striving to break new ground in science to improve humanity; this involves acting rightly for patients, our staff, the planet, and the community, while speeding up our work on diversity and inclusion, all of which we think add to lasting sustainable shareholder value; these matters are all connected; for instance, environmental concerns are fundamental to human health. In that spirit, I take great pride in our just-announced 20-year, $250 million Healthy Climate, Healthy Lives initiative. It features an objective to remove our fossil fuel emissions by 2040 and to drive constructive transformation by furthering research on how fossil fuels affect human health and acting to support climate and health equity. Last, I want to express gratitude to our team members globally, who are committed to creating a beneficial difference in patients' lives, which includes securing access to our treatments amid these difficult times. With that, we'll now take questions.
Terence Flynn
analystHello, and good morning. I appreciate you answering my questions. In getting ready for the AdCom, are there any particularly important new analyses or data points that we ought to anticipate hearing about while you work to present the risk-benefit picture for this drug? Also, congratulations on the filing in Europe. Regarding the European side, is there anything worth pointing out in terms of meaningful similarities or differences compared with what you discussed with the FDA? Thank you.
Alfred Sandrock
executiveHello, this is Al. We have performed a great deal of analysis. That work has been underway for over a year alongside FDA. We — we are putting in tremendous effort, and the team is putting in tremendous effort, getting ready for the AdCom, and we're quite enthusiastic about presenting our point of view that day.
Terence Flynn
analystRegarding the EU, what accounts for the difference there?
Alfred Sandrock
executiveIn the EU, we submitted our filing following a number of formal meetings, and we anticipate receiving feedback and kicking off the engagement process. As for Japan, we've just completed our formal interactions and a filing will follow shortly.
Marc Goodman
analystHi, good morning. My question really concerns expenses. You're set to see $3 billion disappear from TECFIDERA sales, so I was wondering why no restructuring plan or major cost reductions have been announced to help counterbalance that? I get that VUMERITY remains on the market, but there's plainly a mismatch between the revenue from those two products and the large sales figures associated with them; and then as a secondary matter, could you address any consequences for the tax rate stemming from TECFIDERA sales vanishing? Thank you.
Michel Vounatsos
executiveWell, I appreciate that question. Naturally, we're always looking at opportunities to cut costs and operate more efficiently — particularly given that TEC may soon launch in the U.S., which will certainly have a major impact. We were able to take about $400 million out of our infrastructure, making us a leaner and simpler organization, and we've got several efforts in motion focused on streamlining the back office and trying to unlock additional resources. Of course, you have to keep in mind that we still have an MS business worth over $6 billion in a highly competitive market, and we absolutely need to keep investing there to defend our leadership position. Right now VUMERITY doesn't amount to much, yet the signing shows encouraging signals, and we'll revisit that topic later. So we have to keep going and keep putting resources behind the VUMERITY launch, and clearly aducanumab is in the picture too. Lessons from COVID and how we use things also help us become more efficient. Still, we must keep funding the base business. We have to get ready to launch aducanumab, since we're hopeful, and at the same time we genuinely try to hold on to whatever savings we can.
Michael McDonnell
executiveSure, I'll jump in briefly on that, Marc. Appreciate the question — this is Mike. To build a bit on Michel's point and give some additional context: with SG&A sitting near 17% of revenue, we believe that's a fairly efficient level. Like Michel mentioned, we're shifting certain costs and resources toward the aducanumab launch as well as in support of VUMERITY. And clearly we still need to keep backing the MS franchise, though I'd note that the cost savings we've discussed were only part of our guidance for Q4 — we aren't providing guidance for '21 right now. Naturally, though, you wouldn't observe any cost effects from this until 2021, and we'll say more once we get to 2021. Regarding your tax rate question, I think you were responding to something in the prepared remarks. Because of the shift in the cash flow profile and the profitability profile for TECFIDERA, a deferred tax adjustment had to be recorded tied to a valuation allowance, and that had a modest effect on the effective tax rate for the quarter. So I hope that helps.
Michel Vounatsos
executiveIf I could just build on Mike's comments, TECFIDERA remains over $1 billion outside the United States. Even if you take away the U.S. market entirely, it's still expanding. And in certain nations we're in the process of launching TECFIDERA. So we intend to keep investing in the entire MS franchise, which is more than $6 billion, as well as TECFIDERA ex-U.S.
Matthew Harrison
analystGreat. Good morning, and thank you for taking my question. So I suppose, when you consider the Advisory Committee and think through a possible route to approval, how much risk do you see that the FDA might consider approving aducanumab for a particular subgroup of patients, where in their view the risk-benefit looks more favorable than it does across the overall patient population? Any thoughts on that would be useful. And then, Mike, could you also talk about inventory trends during the quarter? Thanks.
Alfred Sandrock
executiveHi, Matthew. It's Al here. We — look, the FDA holds all the data. Our belief remains that substantial evidence of efficacy exists for aducanumab. If that weren't our belief, we would not have filed. And we're eager to present all the data, including possible subgroups, at the FDA Advisory Committee. At this point, it's in the FDA's hands.
Joe Mara
executiveYeah, Joe here. As for what you asked about inventory, I'd simply say it didn't have a meaningful effect this quarter, and it wasn't anything we flagged.
Umer Raffat
analystHey everyone. Appreciate you letting me ask. Michel, I remember how thrilled you seemed when the choice was made to submit to the FDA. Maybe it's simply because this call is being held virtually today, but I'm not really picking up that same energy, at least during this call, regarding the EU submission. Is there a point the EU is bringing up that differs from the FDA? I'd like to hear your thoughts on that, Michel; and Al, I recall that when the data came out, quite a few really significant elements of it weren't visible. My understanding was that those elements likely align with the broader analysis, but could you address whether you think the FDA will zero in on APOE4 carriers as opposed to non carriers? Also, could you remind us whether efficacy holds up across those two groups, and if we considered only patients who didn't have ARIA, would you expect — does the efficacy gap match the overall finding?
Michel Vounatsos
executiveLet me address the first portion of what you asked, Umer. We feel just as enthusiastic regarding every one of our conversations with regulators globally. That said, the U.S. FDA will no doubt have a cascading effect on all of them. In fact, we needed to direct our team's attention back toward the U.S. FDA, since we had gained approvals from other agencies that wished to meet and wanted us to present the data. So I won't get into China or every other market, Australia, Canada, Switzerland, and so on. The clear priority, then, is the U.S. FDA, November 6 — we're enthusiastic and optimistic, and after that the rest should proceed on their own, ideally.
Alfred Sandrock
executiveHey Umer, regarding what you asked about carriers compared with non carriers — listen, I'd rather not guess what the folks at the FDA might put to the advisors during the Advisory Committee. That said, should it reach that stage, we're ready. There's — the thing is — our subgroup data hasn't been presented so far. At some point we'll do that, and it could very well surface at the Advisory Committee, for all I know. Either way, we're keen to lay out how we see the data, no matter what gets raised.
Evan Seigerman
analystHello there. I really appreciate you fielding this. Here's one coming from Michael — good to speak with you over the phone. Given how TECFIDERA has been eroding, what made you decide to greenlight another share repurchase program instead of, let's say, putting your capital to work somewhere else that might boost revenue growth? Beyond aducanumab, what's your approach for tackling this drop in revenue and earnings that's showing up now? Thanks.
Michael McDonnell
executiveOf course. Evan, good to meet you, and I appreciate the question. Well, Biogen has been quite active when it comes to capital allocation for some time. As Michel noted during the prepared remarks, over just the past 4 years, there have been 20 transactions totaling close to $5 billion, and clearly the company has given back substantial capital to shareholders through share buybacks. We anticipate that both of those things will keep going. Clearly, we'll stay active on the BD side, just as the company always has been; and despite what's happening with TECFIDERA, we're holding $4.6 billion in cash as of the close of September. A small level of debt — net debt, I believe, $2.8 billion; we still have extremely strong cash flow and a very pristine balance sheet. And our plan is to use that for both BD and share repurchases, and the rationale behind the share repurchase fits perfectly with that.
Evan Seigerman
analystAll right, that's wonderful. Thanks.
Michel Vounatsos
executiveSo Evan, we're still staying quite busy with BD, and this organization is capable of carrying on with both things at once. We give capital back to the shareholders, and on top of that it contributes to momentum in the business, and we've gotten ready for each of those. We're putting a lot of effort into it.
Evan Seigerman
analystGreat. Thank you.
Phil Nadeau
analystMorning, and I appreciate you fielding my question. Al, I'd like you to answer this one. Several times now, people have raised the topic of the AdCom, yet you've kind of sidestepped what our position will actually be. So I'm wondering whether you might offer us a quick sense of the main pillars of the case you'll make that aducanumab carries a favorable benefit-risk profile. Which portions of the data would you put front and center, and when it comes to the risk side, what's your plan for handling the area? Then I have one more question that builds on that. We're about two weeks out from when those proofing documents are supposed to become public — has Biogen gotten ahold of them at this point? Thanks.
Alfred Sandrock
executiveWell, here's how I'd frame it: what we're arguing hinges on having one study, EMERGE, that came out strongly positive — it hit the pre-specified primary endpoint as well as every secondary one. Then there's the Phase 1b trial, which came out in Nature a few years back, and that one backs us up. On top of that there's ENGAGE, and we think we've got a handle on the reasons it turned out negative, and our view is that this doesn't take anything away from the trial that succeeded. As for what could go wrong, ARIA is really the big one. Our view is that this is something we can handle. We've figured out the right way to approach it, using MRI monitoring and titration. Because of that, we think the benefit-risk profile supports approval. If that weren't our assessment, we never would have submitted the filing. As for the briefing book, we won't be offering any comment on it. According to what's noted in the FDA register, it becomes publicly accessible two days before the Advisory Committee meeting actually takes place.
Michael Yee
analystHello. I appreciate you taking the question. To build on that, could you provide some insight into the wording regarding how the FDA might intend to move ahead sooner? What exactly does that indicate? Does that suggest a much earlier timeline, and maybe you could keep stressing that point; so perhaps give us a bit more detail on it. And if you — if it were to happen early, would you truly be in a position to launch on virtually any given day should that scenario unfold? And should things not play out that way, could you help us properly calibrate where the expenses would be headed? Since I believe you invested heavily — getting ready for this, which reflects optimism, but what would need to be modified? Maybe just some additional context on that. Many thanks.
Alfred Sandrock
executiveI'll handle the initial portion, Michael. Regarding moving ahead sooner, the FDA has possessed the data ever since last June. Our first — immediately following our initial Type C meeting, we forwarded them all the primary data. That might explain why they indicated they could move ahead sooner. And we observe the Advisory Committee is set fairly early compared with the window they have until the PDUFA date of early March. Okay, please continue.
Michel Vounatsos
executiveOn the question of whether we're set to launch, the brief response is an unequivocal affirmative. Our medical team's interactions with scientific experts have kept growing — we've ramped those up. Conversations with payers have taken place. Efforts are underway regarding both the value story and what the price might be. Things are moving forward. A cross-functional group is addressing readiness at the sites. Despite COVID, these people are prepared to gather and to participate. Our digital abilities, which were already quite robust at the outset, have definitely been strengthened further. We've expanded patient engagement along with patient services, since we expect a great many inquiries and calls seeking guidance from patients. Our strategy for a possible launch is highly disciplined, with attention directed initially at the key treatment centers and the specialist, before expanding toward the wider population and, clearly, working with Medicare. Once more, given how enormous the disease burden is, every party we encounter shows considerable enthusiasm, even though in some sense we alone are constructing the infrastructure — something that poses difficulties — yet we're extremely happy with how things are going. We'll be prepared.
Joe Mara
executiveYou address the last part, which is just expenses and …
Michael McDonnell
executiveYeah. I mean, look, I think with any luck, it's obvious that we're optimistic, and what we're preparing for is aducanumab launching successfully, along with the hopefully improbable situation where we don't get approval. Naturally, we'd be required to examine our cost base.
Michael Yee
analystThanks, everyone. That was really useful.
Cory Kasimov
analystExcellent. Morning, folks. Appreciate you taking my question. I wanted to build on a point Michel raised a moment ago regarding pricing. Let me say right away that I'm getting way ahead of myself here. That said, assuming aducanumab gets the green light, could you share your most current thinking on how you might set a price that best captures the product's potential while also ensuring accessibility? And because it seems like everyone is asking the same second thing, just a quick housekeeping item for Michael. SPINRAZA sales fell 10% this quarter — I mean, you pointed to competition and also to the lingering impact of COVID. Could you break that down a bit and give us a rough sense of how much each factor contributed?
Michel Vounatsos
executiveWe're likewise moving forward on what the price of aducanumab could be, assuming approval, though it's still too early to say. That said, we're in broad discussions with pharmacoeconomists, ICER, and other advisers. As I mentioned in the note before, society bears such a heavy cost; we're certainly working to assess with great clarity the clinical meaningfulness and the value aducanumab would deliver across the different customer groups, beginning with patients, caregivers, and payers, plus everything tied to that value creation aducanumab would generate — not just in year one, but across the product's whole lifespan, perhaps even past the patent, once it lapses; so it's premature. We'll revisit this, and we're on it. We've got a great deal of, I'd say, earnest attention, commitment, and guidance from others.
Michael McDonnell
executiveOkay, Cory, regarding the latter portion of what you asked, I'll attempt to provide a few figures that I hope prove useful, and I'll basically talk in year-over-year comparisons. So on a worldwide basis, SPINRAZA declined 10% year-over-year. And in a number of the charts we've posted, you'll notice that the patient count actually rose 21% year-over-year, and several factors feed into these dynamics. The first is product dosing dynamics. As the product matures, we have fewer loading doses compared with maintenance doses. The second factor is COVID impacts. We cannot give you that figure with precision. It's somewhat difficult to isolate, but certainly when we observe fewer new patients being added who move through loading doses, along with some dosing delays, we understand that a portion of the cause is tied to COVID and patients not coming in to receive those treatments. There's also some country mix involved here, if you will, and a portion of the patient growth we've recorded is originating from countries where pricing is lower. And finally, there's competition from ZolGensma and Evrysdi. So all of those are essentially part of the mix when trying to state precisely what the COVID portion is. It isn't something we can fully isolate; we know it's part of the mix, and hopefully those metrics I provided are at least somewhat helpful.
Cory Kasimov
analystYes, definitely. Thank you.
Michael McDonnell
executiveThank you.
Ronny Gal
analystNice work, and thanks for taking my question. First, I just want to make sure I understand something. It was also good to meet you by phone earlier. The gist regarding our expense base seems to be that we may need to review it, yet the decision on how to proceed will be postponed until the aducanumab results are known. I just want confirmation that this is the takeaway when we consider our cost structure for 2021. Secondly, remaining on the SMA topic, could you provide some sense of what portion of new patient starts you hold within the United States and abroad, so we might build a projection for how the market will be divided?
Michael McDonnell
executiveOf course. Ronny, this is Mike here. Regarding your reading of the costs, as we already mentioned, we are preparing for an aducanumab launch, and that does create additional strain on SG&A. That is clearly something we are concentrating on and intend to handle properly. We have shifted certain resources, as I noted during the prepared remarks, away from TECFIDERA toward aducanumab and also to back VUMERITY. Our support for the MS platform will carry on. Per Michel's comment, we hold a franchise worth more than $1 billion outside the United States in TECFIDERA, and that is worth keeping in mind. So that roughly describes where things stand regarding the fourth quarter guidance we provided today. We will share additional details on all our financial metrics once we move into 2021 and presumably offer guidance for next year at that point.
Alfred Sandrock
executiveYeah, Ronny, regarding the latter portion of what you asked — I don't believe we've reached that degree of specificity when it comes to things like shares in new starts and so forth.
Michel Vounatsos
executiveIf you'd like, though, I can provide some additional detail regarding the market trends we're observing—particularly within the United States following a recent introduction. The combination of that launch with the COVID situation has definitely led to some patients moving away from SPINRAZA, which makes sense given how convenient the alternative seems. However, the SUNFISH findings make certain constraints quite apparent, largely due to possible target toxicity along with the 5 milligram cap, which could reduce effectiveness as the kit's weight <<inaudible>> rises and as both patients and doctors begin to recognize this. Even so, when a launch happens, people are drawn in by the idea of an oral treatment, yet it's far from simple—taking it 365 times per year with a difficult dosing schedule, compared to just 3 times per year and knowing you've received the dose. Thus, drawing on the data available to us and all the real-world evidence spanning presymptomatic infants through symptomatic adults, ultimately the safety and efficacy profile will likely win out, ought to win out. That's the reason we stay fairly hopeful regarding SPINRAZA once this surge of excitement has somewhat subsided.
Ronny Gal
analystAll right, I appreciate it.
Geoff Meacham
analystHi everyone, thanks for asking. There were a few things I wanted to touch on quickly. Michel, if the panel comes back unfavorably or the FDA decides not to grant approval, which adjustments to the strategy do you see as possible? Should it lean toward more aggressive BD, would the $5 billion buyback that was announced today rule out the possibility of pursuing a bigger, more transformational deal? Then a quick follow-up regarding SPINRAZA. Could you give us a directional sense of how much of the switch dynamic was at play in the U.S. this quarter, and would that serve as an indicator for the larger OUS market? Thanks so much.
Michel Vounatsos
executiveSo, beginning with SPINRAZA, roughly 200 patients were being switched, unless I'm wrong, to the new launch each day. That said, we remain confident that SPINRAZA will, over time, continue as the foundational therapy for treating SMA. As for your first question about what I think regarding the strategy. Well, let me begin by reminding you that our assessment keeps us optimistic about the potential launch of ADU, and that is the assumption underneath. Even so, should ADU fail, our position is still very strong. We appear to be very profitable. Our pipeline is deep, our balance sheet is strong, and we hold a large portfolio in CNS, which will allow for long-term growth and value creation. So the binary event does not necessarily define the prospects, though they will certainly be impacted if ADU fails. There's a pipeline for us, and opportunity in optha, in stroke, in lupus, in ALS and biosimilars. There's the bigger deal with Denali. There's the rest of the portfolio in AD, the leadership position in neurodegenerative disease still here, and overall we have 30 clinical assets, 8 filed, or in Phase 3. Plus we have the entire portfolio with life cycle management opportunities. And as I mentioned, my belief is that SMA, SPINRAZA will remain the foundational therapy. So cost discipline will always be present, as Mike discussed.
Michael McDonnell
executiveRight, and one more thing I’d like to mention — you brought up whether the buyback authorization blocks BD, and like we’ve said previously, it does not. Both will keep happening. Also worth keeping in mind, that authorization is quite flexible. It carries no expiration date. So we’ll keep doing both and stay active, and our balance sheet sits in a really strong spot, which makes us happy.
Geoff Meacham
analystOkay. Thank you.
Michael McDonnell
executiveThank you.
Sumant Kulkarni
analystMorning, and thanks for the chance to ask. Assuming aducanumab gets the green light, would you anticipate that a formal risk evaluation and litigation strategy program gets established? We understand you've stated that you're prepared to launch on day one, but how about the infrastructure needed to handle the burden a potential REMS program could create?
Alfred Sandrock
executiveAl here. When it comes to REMS, that's difficult to determine right now. The review process is still ongoing. What I can say is that our view is that ARIA's risk can be managed, and over the years the community has figured out how to handle that risk. If a REMS is needed for that, the FDA will decide.
Sumant Kulkarni
analystThanks.
Joe Mara
executiveCould you say that again — the remaining portion of what you asked, if that's okay with you?
Sumant Kulkarni
analystRegarding the support systems needed to handle the load a possible REMS program could create — would those be set up if a program of that kind becomes necessary?
Alfred Sandrock
executiveWe have handled this kind of thing previously, and we understand the process for running REMS programs, whichever form they take. So yes, we could be prepared for it, and that covers the training component, which tends to rank among the most critical elements of any REMS program.
Sumant Kulkarni
analystUnderstood. Thanks.
Jay Olson
analystHello, and thanks for letting me ask a couple of questions. I want to change topics and turn to Parkinson's disease. Since you're a leader in neurodegeneration, might you describe how you see future Parkinson's disease treatment shaping up, given that you possess an alpha-synuclein antibody, there have lately been signs of efficacy coming from Prothena and Roche, you also run an LRRK2 program together with Denali, and several gene therapies are being developed by rivals. So among these strategies, which strikes you as having the greatest promise, and how does Biogen position itself within the competitive landscape? Thanks.
Alfred Sandrock
executiveYes, many thanks. We — we feel a great deal of enthusiasm regarding what may be possible in Parkinson's disease. As you noted, the antibody from Prothena and Roche appeared to show some efficacy on Parts 2 and 3, I believe, of the UPDRS score, backed further by digital measures plus certain imaging outcome measures, as were presented roughly a month ago at the Movement Disorder Society meeting. And we possess our own antibody targeting alpha-synuclein. Ours differs, because it is more specific toward aggregated forms of alpha-synuclein, and a readout should arrive over the next few months. We additionally have an antisense oligonucleotide program aimed at alpha-synuclein. You mentioned the LRRK2 inhibitor; ours is the lead program in that area, the Denali 151 program, an oral small molecule LRRK2 inhibitor; and it might work not only among patients carrying LRRK2 mutations, but there is also abundant evidence of lysosomal hypofunction in other PD cases, including patients lacking LRRK2 mutations. Thus the possibility exists that it might work across a broad range of Parkinson's patients. Then, as you noted regarding another lysosomal gene, arguably GBA, patients homozygous for GBA develop Gaucher's disease, or lysosomal storage disease. Those who are heterozygous face a heightened risk of Parkinson's disease. Consequently, we have preclinical programs aimed at that too. And as I mentioned, we can license two programs through the Transport Vehicle program. I would add as well that earlier this year we struck a deal with Sangamo, encompassing not only possible gene therapy programs for Alzheimer's disease but for Parkinson's disease too. Among our lead efforts there is a gene therapy program targeting alpha-synuclein; so, I believe there's a broad range. I believe there are many very good, validated targets, validated through human genetics and through clinical pathologic data in humans, and we have multiple modalities — gene therapies, small molecules, and antisense oligonucleotides — available to us.
Joe Mara
executiveThanks. We’re grateful for every question; we likely have room for roughly one additional one.
Brian Abrahams
analystHi there. I really appreciate you letting me ask. You mentioned certain extra regulatory discussions held beyond America regarding aducanumab. I'd like to know about what you heard from Japan — especially how the Phase 1/2 trial you ran there might roll out, and do you think regulators outside the U.S., like Japan's, could move sooner? Then, very briefly on the MS business: you have multiple next-gen candidates such as 091, 107, and 061, yet each is fairly early and would likely launch only after further exclusivity losses. So how are you viewing that lifecycle — do you lean toward cutting costs over the long haul until those mature, or would you rather build up the mid-stage MS pipeline to make use of the commercial setup already in place? Thank you.
Alfred Sandrock
executiveBrian, regarding filings beyond the U.S., well, like Michel stated, our optimism about submissions outside America is just as strong; we simply are less far along procedurally — we only just submitted to EMA, and Japan hasn't received a filing from us at all yet. Thus we're keen to get those regulatory processes underway. And, as Michel noted, our optimism is just as strong. As for the second part …
Michel Vounatsos
executiveRegarding MS lifecycle management, our clinical program and the advancements across our MS portfolio and pipeline have never been as extensive. The early pipeline includes BTK, along with all the possibilities to develop or co-develop certain products of ours, and we also have lifecycle management possibilities involving TYSABRI, the EIV, subcu, Avonex with a new label, and Plegridy, IM. Consequently, we have abundant chances to generate market events. And as you observed, notwithstanding the possible launch of a high efficacy product, aducanumab, which makes the class—the segment—become extremely crowded, TYSABRI keeps performing very well, since it is very well documented and well appreciated by the patients and the physicians. Thus, we remain confident in the remainder of the portfolio, I would say, beyond the challenging situation we are facing with the TEC in the U.S. There is a whole franchise beyond this very specific case. And the commitment of the company beyond RMS for remuneration <<inaudible>> over the long-term. So, Biogen continues to support MS like day one. So, thank you all for your attention. Exciting time at Biogen, and we are all looking forward to early November for more news from the AdCom and looking forward to taking the company to the next step after this event. Thank you all. Have a good day.
Operator
operatorThat brings us to the end of today's call, everyone, and we appreciate your joining us. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.